A Single Dose Study to Evaluate the Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
Latest Information Update: 28 Feb 2025
At a glance
- Drugs Insulin efsitora alfa (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 03 Dec 2024 Planned primary completion date changed from 1 Nov 2025 to 1 Nov 2026.
- 17 Oct 2024 Status changed from not yet recruiting to recruiting.
- 24 Sep 2024 Planned initiation date changed from 1 Aug 2024 to 1 Sep 2024.